doi: 10.1161/JAHA.122.028892 3
The primary predictors are individual sensitivity and the rate of dose escalation
In short it combines the benefits of a GLP-1 agonist with another peptide that also is released within the intestines acting on similar pathways creating an incretin effect that provides improved insulin sensitivity and appetite control than GLP-1 agonists alone
One such route is, of course, through the NHS , which, crucially, also incorporates a diet and exercise plan
Across the SURMOUNT clinical trial programme (the pivotal obesity studies evaluating tirzepatide), alopecia was reported in approximately 4% to 6% of participants receiving the drug, compared to around 1% in the placebo groups
So as soon as you lose some weight and see youre not losing weight anymore, a large percentage stop taking it